LAVA Therapeutics
- Country
- 🇳🇱Netherlands
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 35
- Market Cap
- $48.6M
- Introduction
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Biological: LAVA-1207Biological: LAVA-1207 plus Pembrolizumab
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Lava Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT05369000
- Locations
- 🇺🇸
UCSF Medical Center at Parnassus, San Francisco, California, United States
🇺🇸M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center - Duke Cancer Center, Durham, North Carolina, United States
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML
- Conditions
- Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia
- Interventions
- Biological: LAVA-051Biological: Interleukin 2
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Lava Therapeutics
- Target Recruit Count
- 102
- Registration Number
- NCT04887259
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States